Prognostic and therapeutic implications of aromatase expression in lung adenocarcinomas with EGFR mutations

Clinical Cancer Research

Volumn 20, Issue 13, 2014, Pages 3613-3622

  Kohno, Mikihiro ^a   Okamoto, Tatsuro ^a   Suda, Kenichi ^a   Shimokawa, Mototsugu ^b   Kitahara, Hirokazu ^a   Shimamatsu, Shinichiro ^a   Konishi, Hideyuki ^a,c   Yoshida, Tsukihisa ^a   Takenoyama, Mitsuhiro ^b   Yano, Tokujiro ^d   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION BEPPU MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EXEMESTANE; MESSENGER RNA; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR;

ADENOCARCINOMA CELL LINE; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DRUG SENSITIVITY; EGFR GENE; FEMALE; GENE EXPRESSION; GENE MUTATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SEX DIFFERENCE; SMOKING; VERY ELDERLY; ADENOCARCINOMA; CANCER GRADING; CANCER STAGING; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PROGNOSIS; RISK FACTOR; TUMOR CELL LINE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AROMATASE; AROMATASE INHIBITORS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS; RNA, MESSENGER;

EID: 84903841837     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2683     Document Type: Article

References (45)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61: 69-90.
2. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers-a different disease. Nat Rev Cancer 2007;7: 778-90.
3. Yano T, Miura N, Takenaka T, Haro A, Okazaki H, Ohba T, et al. Neversmoking nonsmall cell lung cancer as a separate entity: clinicopathologic features and survival. Cancer 2008;113: 1012-8.
4. Yano T, Haro A, Shikada Y, Maruyama R, Maehara Y. Non-small cell lung cancer in never smokers as a representative 'non-smokingassociated lung cancer': epidemiology and clinical features. Int J Clin Oncol 2011;16: 287-93.
5. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97: 339-46.
6. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64: 8919-23.
7. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27: 4247-53.
8. Patrone C, Cassel TN, Pettersson K, Piao YS, Cheng G, Ciana P, et al. Regulation of postnatal lung development and homeostasis by estrogen receptor β. Mol Cell Biol 2003;23: 8542-52.
9. Stabile LP, Davis AL, Gubish CT, Hopkins TM, Luketich JD, Christie N, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor α and β and show biological responses to estrogen. Cancer Res 2002;62: 2141-50.
10. Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 2005;65: 1459-70.
11. Pietras RJ, Marquez DC, Chen HW, Tsai E, Weinberg O, Fishbein M. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 2005;70: 372-81.
12. Weinberg OK, Marquez-Garban DC, Fishbein MC, Goodglick L, Garban HJ, Dubinett SM, et al. Aromatase inhibitors in human lung cancer therapy. Cancer Res 2005;65: 11287-91.
13. Mah V, Seligson DB, Li A, Márquez DC, Wistuba II, Elshimali Y, et al. Aromatase expression predicts survival in women with early-stage non-small cell lung cancer. Cancer Res 2007;67: 10484-90.
14. Raso MG, Behrens C, Herynk MH, Liu S, Prudkin L, Ozburn NC, et al. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 2009;15: 5359-68.
15. Nose N, Sugio K, Oyama T, Nozoe T, Uramoto H, Iwata T, et al. Association between estrogen receptor-β expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol 2009;27: 411-7.
16. Stabile LP, Dacic S, Land SR, Lenzner DE, Dhir R, Acquafondata M, et al. Combined analysis of estrogen receptor β-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin Cancer Res 2011;17: 154-64.
17. Liu Y, Inoue M, Sobue T, Tsugane S. Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women: a large-scale population-based cohort study. Int J Cancer 2005;117: 662-6.
18. Chlebowski RT, Schwartz AG, Wakelee H, Anderson GL, Stefanick ML, Manson JE, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a posthoc analysis of a randomised controlled trial. Lancet 2009;374: 1243-51.
19. Slatore CG, Chien JW, Au DH, Satia JA, White E. Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. J Clin Oncol 2010;28: 1540-6.
20. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350: 1081-92.
21. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S, et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 1994;15: 342-55.
22. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003;348: 2431-42.
23. Niikawa H, Suzuki T, Miki Y, Suzuki S, Nagasaki S, Akahira J, et al. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res 2008;14: 4417-26.
24. Hershberger PA, Stabile LP, Kanterewicz B, Rothstein ME, Gubish CT, Land S, et al. Estrogen receptor β (ERβ) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells. J Steroid Biochem Mol Biol 2009;116: 102-9.
25. Garon EB, Pietras RJ, Finn RS, Kamranpour N, Pitts S, Márquez-Garbán DC, et al. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer. J Thorac Oncol 2013;8: 270-8.
26. Nose N, Uramoto H, Iwata T, Hanagiri T, Yasumoto K. Expression of estrogen receptor β predicts a clinical response and longer progression-free survival after treatment with EGFR-TKI for adenocarcinoma of the lung. Lung Cancer 2011;71: 350-5.
27. Sun HB, Zheng Y, Ou W, Fang Q, Li P, Ye X, et al. Association between hormone receptor expression and epidermal growth factor receptor mutation in patients operated on for non-small cell lung cancer. Ann Thorac Surg 2011;91: 1562-7.
28. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Tumours of the lung, pleura, thymus and heart. Pathology and genetics. Lyon: IARC Press; 2004.
29. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNMstage groupings in the forthcoming (seventh) edition of the TNM Classification of Malignant Tumours. J Thorac Oncol 2007; 2: 706-14.
30. Nagai Y, Miyazawa H, Huqun, Tanaka T, Udagawa K, Kato M, et al. Genetic heterogeneity of the epidermal growth factor receptor in nonsmall cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005;65: 7276-82.
31. Suda K, Tomizawa K, Fujii M, Murakami H, Osada H, Maehara Y, et al. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol 2011;6: 1152-61.
32. Tomizawa K, Suda K, Onozato R, Kuwano H, Yatabe Y, Mitsudomi T. Analysis of ERBB4 mutations and expression in Japanese patients with lung cancer. J Thorac Oncol 2010;5: 1859-61.
33. Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, Sekido Y, et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 2010;16: 5489-98.
34. Siegfried JM, Hershberger PA, Stabile LP. Estrogen receptor signaling in lung cancer. Semin Oncol 2009;36: 524-31.
35. Verma MK, Miki Y, Sasano H. Aromatase in human lung carcinoma. Steroids 2011;76: 759-64.
36. Miki Y, Abe K, Suzuki S, Suzuki T, Sasano H. Suppression of estrogen actions in human lung cancer. Mol Cell Endocrinol 2011;340: 168-74.
37. Cheng G, Weihua Z, Warner M, Gustafsson JA. Estrogen receptors ER α and ER β in proliferation in the rodent mammary gland. Proc Natl Acad Sci U S A 2004;101: 3739-46.
38. Ishibashi H, Suzuki T, Suzuki S, Niikawa H, Lu L, Miki Y, et al. Progesterone receptor in non-small cell lung cancer-a potent prognostic factor and possible target for endocrine therapy. Cancer Res 2005;65: 6450-8.
39. Abe K, Miki Y, Ono K, Mori M, Kakinuma H, Kou Y, et al. Highly concordant coexpression of aromatase and estrogen receptor β in non-small cell lung cancer. Hum Pathol 2010;41: 190-8.
40. Oyama T, Kagawa N, Sugio K, Uramoto H, Hatano O, Harada N, et al. Expression of aromatase CYP19 and its relationship with parameters in NSCLC. Front Biosci 2009;14: 2285-92.
41. Koutras A, Giannopoulou E, Kritikou I, Antonacopoulou A, Evans TR, Papavas-siliou AG, et al. Antiproliferative effect of exemestane in lung cancer cells. Mol Cancer 2009;24: 109.
42. Marquez-Garban DC, Chen HW, Fishbein MC, Goodglick L, Pietras RJ. Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids 2007;72: 135-43.
43. Márquez-Garbán DC, Chen HW, Goodglick L, Fishbein MC, Pietras RJ. Targeting aromatase and estrogen signaling in human non-small cell lung cancer. Ann NY Acad Sci 2009;1155: 194-205.
44. Miki Y, Suzuki T, Abe K, Suzuki S, Niikawa H, Iida S, et al. Intratumoral localization of aromatase and interaction between stromal and parenchymal cells in the non-small cell lung carcinoma microenvironment. Cancer Res 2010;70: 6659-69.
45. Traynor AM, Schiller JH, Stabile LP, Kolesar JM, Eickhoff JC, Dacic S, et al. Pilot study of gefitinib and fulvestrant in the treatment of postmenopausal women with advanced non-small cell lung cancer. Lung Cancer 2009;64: 51-9.